Lycia Therapeutics Inc LYCA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $28.85
- Day Range
- $24.63–28.00
- 52-Week Range
- $22.19–36.49
- Bid/Ask
- $10.50 / $26.76
- Shares Outstanding
- 52.09M
- Market Cap
- $1.36B
- Volume/Avg
- 8 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 171.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.lyciatx.com
Valuation
|
Metric
|
LYCA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 171.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LYCA
|
|---|---|
Quick Ratio | 12.26 |
Current Ratio | 12.60 |
Interest Coverage | −1,306.92 |
Quick Ratio
LYCA
Profitability
|
Metric
|
LYCA
|
|---|---|
Return on Assets (Normalized) | −22.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LYCA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^CMD?< | LOCK|?Q<Lt | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?CHVxX | LOCK|?jn% | $84B | |||
| Moderna Inc
MRNA
| LOCK|#j!pTVr | LOCK|$Lm | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!%Qf#^$ | LOCK|hk& | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s&fKRR | LOCK|d? | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bD!K%&! | LOCK|zX@d | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|tvF!P$@Y | LOCK|v?#L | $29B | |||
| Incyte Corp
INCY
| LOCK|@HY@!<b | LOCK|YqR | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|r<^Zq#Z | LOCK|$Sc | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%!@&?< | LOCK|Fz? | $14B |
United States